Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBITDA (2016 - 2025)

Arrowhead Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at $28.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 116.21% year-over-year to $28.5 million; the TTM value through Dec 2025 reached $236.1 million, up 136.66%, while the annual FY2025 figure was $31.8 million, 105.29% up from the prior year.
  • EBITDA reached $28.5 million in Q4 2025 per ARWR's latest filing, up from $17.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $368.1 million in Q1 2025 to a low of -$177.7 million in Q2 2025.
  • Average EBITDA over 5 years is -$52.5 million, with a median of -$67.8 million recorded in 2021.
  • Peak YoY movement for EBITDA: crashed 366.45% in 2024, then skyrocketed 390.23% in 2025.
  • A 5-year view of EBITDA shows it stood at -$62.9 million in 2021, then soared by 33.35% to -$41.9 million in 2022, then tumbled by 218.15% to -$133.4 million in 2023, then tumbled by 31.8% to -$175.8 million in 2024, then skyrocketed by 116.21% to $28.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's EBITDA are $28.5 million (Q4 2025), $17.2 million (Q3 2025), and -$177.7 million (Q2 2025).